HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Abstract
VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.
AuthorsJohn M L Ebos, Roberto Pili
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 18 Issue 14 Pg. 3719-21 (Jul 15 2012) ISSN: 1557-3265 [Electronic] United States
PMID22679177 (Publication Type: Journal Article)
Chemical References
  • Vascular Endothelial Growth Factor A
Topics
  • Animals
  • Cell Proliferation
  • Clinical Trials as Topic
  • Endothelial Cells (cytology)
  • Humans
  • Mice
  • Neoplasms (therapy)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: